Yatharth Hospital & Trauma Care Services Ltd (YATHARTH) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- The company will receive 3,150 crores from Advent International to fund an aggressive expansion to 7,000-8,000 beds, prioritizing acquisitions of EBITDA-positive hospital chains.
- Management reaffirmed its 24% EBITDA margin guidance, stating the 0.3% margin impact from cancer drug price caps will be offset by operational efficiencies.
- The new Delhi (Model Town) hospital is on track for EBITDA breakeven by December 2026, validating the company's turnaround strategy for acquired assets.
Performance Overview
- Yatharth Hospital reported its strongest quarter to date, driven by a 52% year-on-year revenue growth and a 50% EBITDA growth.
- The company entered into a strategic partnership with Advent International for a primary capital investment of 3,150 crores to accelerate expansion.
- Newer hospitals are ramping up significantly, now contributing 28% to group revenue compared to 11% in the prior year, and have collectively turned EBITDA positive.
- Average Revenue Per Occupied Bed (ARPOB) increased by 11% year-on-year to approximately 36,000, with newer premium hospitals showing ARPOBs above 50,000.
- Overall occupancy stood at a healthy 72% for operationalized beds, with mature hospitals like Noida and Jhansi-Orchha operating above 90% occupancy.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.